Examining how gender affects the safety and effectiveness of lenvatinib in thyroid cancer treatment
Observational Study on Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer
This study looks at how gender affects the safety and effectiveness of the thyroid cancer drug lenvatinib in men and women to see if treatment outcomes differ between them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Regina Elena Cancer Institute Academic / other |
| Drugs / interventions | lenvatinib |
| Locations | 1 site (Rome) |
| Trial ID | NCT05789667 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the safety and toxicity profile of lenvatinib in male and female patients with radioiodine refractory differentiated thyroid cancer. It aims to assess gender differences in adverse events, response rates, progression-free survival, overall survival, and duration of response. The study will analyze data from patients treated with lenvatinib to understand how gender influences treatment outcomes. By focusing on these differences, the study seeks to provide insights that could optimize treatment strategies for both genders.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients with radioiodine refractory differentiated thyroid cancer who are being treated with lenvatinib.
Not a fit: Patients under 18 years of age will not benefit from this study as they are excluded from participation.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment approaches for patients with differentiated thyroid cancer based on gender.
How similar studies have performed: While there have been studies on lenvatinib's efficacy, this specific focus on gender differences in treatment outcomes is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with refractory iodine DTC treated with lenvatinib * Signed written informed consent Exclusion Criteria: \- Age \< 18 years
Where this trial is running
Rome
- Regina Elena National Cancer Institute — Rome, Italy (Recruiting)
Study contacts
- Principal investigator: Marialuisa Appetecchia, Prof — Regina Elena Cancer Institute
- Study coordinator: Marialuisa Appetecchia, Prof
- Email: marialuisa.appetecchia@ifo.it
- Phone: 00390652666026
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.